
Opinion|Videos|September 11, 2024
Recommendations and Outlook for Central Precocious Puberty
Experts offer recommendations for supporting central precocious puberty patients in managing the social stigma and challenges associated with their condition.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide any recommendations on supporting patients navigating stigmas and social hardships associated with CPP?
- Please provide any closing thoughts regarding your clinical experience with the management of CPP and your outlook of the future.
Advertisement
Related to this article

The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.

FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.

Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.

Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.

In a Hirschsprung disease mouse model, diet shifted gut microbes and inflammation, with a 3-fold survival difference between standard diets.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
3
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
4
FAQ: How should pediatricians hand off teens with diabetes?
5

